Cargando…
Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants
OBJECTIVE: To evaluate changes in blood long-chain polyunsaturated fatty acid (LCPUFA) and oxylipin concentrations in very preterm infants from birth to 36 weeks’ postmenstrual age (WPA) after providing an emulsified arachidonic acid (ARA):docosahexaenoic acid (DHA) supplement at two different conce...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452757/ https://www.ncbi.nlm.nih.gov/pubmed/36090567 http://dx.doi.org/10.3389/fped.2022.947221 |
_version_ | 1784784982631251968 |
---|---|
author | Álvarez, Patricia Ramiro-Cortijo, David Montes, María Teresa Moreno, Bárbara Calvo, María V. Liu, Ge Esteban Romero, Ana Ybarra, Marta Cordeiro, Malaika Clambor Murube, Marina Valverde, Eva Sánchez-Pacheco, Aurora Fontecha, Javier Gibson, Robert Saenz de Pipaon, Miguel |
author_facet | Álvarez, Patricia Ramiro-Cortijo, David Montes, María Teresa Moreno, Bárbara Calvo, María V. Liu, Ge Esteban Romero, Ana Ybarra, Marta Cordeiro, Malaika Clambor Murube, Marina Valverde, Eva Sánchez-Pacheco, Aurora Fontecha, Javier Gibson, Robert Saenz de Pipaon, Miguel |
author_sort | Álvarez, Patricia |
collection | PubMed |
description | OBJECTIVE: To evaluate changes in blood long-chain polyunsaturated fatty acid (LCPUFA) and oxylipin concentrations in very preterm infants from birth to 36 weeks’ postmenstrual age (WPA) after providing an emulsified arachidonic acid (ARA):docosahexaenoic acid (DHA) supplement at two different concentrations. STUDY DESIGN: This prospective, randomized trial assigned infants to receive a supplement (1) 80:40 group (80 mg/kg/day ARA and 40 mg/kg/day DHA, n = 9) or (2) 120:60 group (120 mg/kg/day ARA and 60 mg/kg/day DHA, n = 9). Infants received supplement daily from birth until 36 WPA. At baseline, 21 days of life and 36 WPA, the LCPUFAs were measured in plasma by gas chromatography/mass spectrophotometry. Additionally, LCPUFAs and oxylipins were analyzed in whole blood by ultra-high-performance liquid chromatography-tandem mass spectrometry. Furthermore, a sample of oral mucosa was obtained to analyze single-nucleotide polymorphism located in the FADS1 gene by PCR. RESULTS: Gestational age was similar between groups (80:40 = 28(+6) [27(+3); 30(+3)] completed weeks(+days); 120:60 = 29(+6) [27(+3); 30(+5)] completed weeks(+days), p = 0.83). At 36 WPA, the change in plasma ARA was significantly different between groups (80:40 group = 0.15 [−0.67; 0.69] %nmol, 120:60 = 1.68 [1.38; 3.16] %nmol, p = 0.031). In whole blood, the levels of ARA-derived oxylipins (5-, 8-, 9-, 11-, 15-HETE and 8,9-EET) and EPA-derived oxylipins (18-HEPE) significantly increase from baseline to 36 WPA in the 120:60 group than the 80:40 group. CONCLUSION: Supplementation at high doses (120:60 mg/kg/day) increased levels of ARA, and EPA- and ARA-derived oxylipins compared to low doses (80:40 mg/kg/day). Differences were detected in EPA metabolites without a significant increase in plasma DHA. |
format | Online Article Text |
id | pubmed-9452757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94527572022-09-09 Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants Álvarez, Patricia Ramiro-Cortijo, David Montes, María Teresa Moreno, Bárbara Calvo, María V. Liu, Ge Esteban Romero, Ana Ybarra, Marta Cordeiro, Malaika Clambor Murube, Marina Valverde, Eva Sánchez-Pacheco, Aurora Fontecha, Javier Gibson, Robert Saenz de Pipaon, Miguel Front Pediatr Pediatrics OBJECTIVE: To evaluate changes in blood long-chain polyunsaturated fatty acid (LCPUFA) and oxylipin concentrations in very preterm infants from birth to 36 weeks’ postmenstrual age (WPA) after providing an emulsified arachidonic acid (ARA):docosahexaenoic acid (DHA) supplement at two different concentrations. STUDY DESIGN: This prospective, randomized trial assigned infants to receive a supplement (1) 80:40 group (80 mg/kg/day ARA and 40 mg/kg/day DHA, n = 9) or (2) 120:60 group (120 mg/kg/day ARA and 60 mg/kg/day DHA, n = 9). Infants received supplement daily from birth until 36 WPA. At baseline, 21 days of life and 36 WPA, the LCPUFAs were measured in plasma by gas chromatography/mass spectrophotometry. Additionally, LCPUFAs and oxylipins were analyzed in whole blood by ultra-high-performance liquid chromatography-tandem mass spectrometry. Furthermore, a sample of oral mucosa was obtained to analyze single-nucleotide polymorphism located in the FADS1 gene by PCR. RESULTS: Gestational age was similar between groups (80:40 = 28(+6) [27(+3); 30(+3)] completed weeks(+days); 120:60 = 29(+6) [27(+3); 30(+5)] completed weeks(+days), p = 0.83). At 36 WPA, the change in plasma ARA was significantly different between groups (80:40 group = 0.15 [−0.67; 0.69] %nmol, 120:60 = 1.68 [1.38; 3.16] %nmol, p = 0.031). In whole blood, the levels of ARA-derived oxylipins (5-, 8-, 9-, 11-, 15-HETE and 8,9-EET) and EPA-derived oxylipins (18-HEPE) significantly increase from baseline to 36 WPA in the 120:60 group than the 80:40 group. CONCLUSION: Supplementation at high doses (120:60 mg/kg/day) increased levels of ARA, and EPA- and ARA-derived oxylipins compared to low doses (80:40 mg/kg/day). Differences were detected in EPA metabolites without a significant increase in plasma DHA. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9452757/ /pubmed/36090567 http://dx.doi.org/10.3389/fped.2022.947221 Text en Copyright © 2022 Álvarez, Ramiro-Cortijo, Montes, Moreno, Calvo, Liu, Esteban Romero, Ybarra, Cordeiro, Clambor Murube, Valverde, Sánchez-Pacheco, Fontecha, Gibson and Saenz de Pipaon. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Álvarez, Patricia Ramiro-Cortijo, David Montes, María Teresa Moreno, Bárbara Calvo, María V. Liu, Ge Esteban Romero, Ana Ybarra, Marta Cordeiro, Malaika Clambor Murube, Marina Valverde, Eva Sánchez-Pacheco, Aurora Fontecha, Javier Gibson, Robert Saenz de Pipaon, Miguel Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants |
title | Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants |
title_full | Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants |
title_fullStr | Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants |
title_full_unstemmed | Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants |
title_short | Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants |
title_sort | randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452757/ https://www.ncbi.nlm.nih.gov/pubmed/36090567 http://dx.doi.org/10.3389/fped.2022.947221 |
work_keys_str_mv | AT alvarezpatricia randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT ramirocortijodavid randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT montesmariateresa randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT morenobarbara randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT calvomariav randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT liuge randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT estebanromeroana randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT ybarramarta randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT cordeiromalaika randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT clambormurubemarina randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT valverdeeva randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT sanchezpachecoaurora randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT fontechajavier randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT gibsonrobert randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants AT saenzdepipaonmiguel randomizedcontrolledtrialofearlyarachidonicacidanddocosahexaenoicacidenteralsupplementationinverypreterminfants |